such as complement dependent cytotoxicity CDC) and antibody dependent cell-mediated cytotoxicity (ADCC), making human IgG1 a natural and desirable choice for therapeutic antibody development in oncology. Considerable effort has focused on improving the stability and Fc function of this IgG1 subclass through protein and glycan engineering. 2-8 Twenty-two of 27 FDA approved therapeutic antibodies belong to the human IgG1 